Pasar al contenido principal

MECANISMOS DE ACCION DEL BLOQUEO DUAL DE LA ENDOTELINA Y EL SGLT2 EN LA PROTECCION CARDIORENAL EN LA DIABETES TIPO 2.

PI17/00257

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (FIMIM)
Centro realización INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (IMIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Epidemiology of Immune-Mediated Glomerulopathies before and after SARS-CoV-2 Vaccination: A Tertiary Referral Hospital Experience

  • Zamora Carrillo, Jorge Iván
  • Lopez Martinez, Marina
  • Patricio Liebana, Marc
  • León Román, Juan
  • Bermejo Garcia, Sheila
  • Vergara Arana, Ander
  • Agraz Pamplona, Irene
  • Azancot Rivero, M Antonieta
  • Toapanta Gaibor, Nestor Gabriel
  • Gabaldon Dominguez, Alejandra
  • Soler Romeo, Maria Jose
  • Ramos Terrades, Natalia
SARS-CoV-2; Immune-mediated glomerulopathy; Vaccine, SARS-CoV-2; Glomerulopatía inmunomediada; Vacuna, SARS-CoV-2; Glomerulopatia immunomediada; Vacuna, Background: Vaccination is a known trigger for the appearance of immune-mediated glomerulopathies (IMG). The appearance of IMG after SARS-CoV-2 vaccination with suspected causality has been described. Our aim is to analyze the incidence of IMG flares before and after SARS-CoV-2 vaccination in our center. Methods: All persons with native kidney biopsy (KB) from January 2019 to March 2022 in our center were included in the study. We compared the incidence of IMG before and after the start of vaccination. We also collected information about whether the patients had received a SARS-CoV-2 vaccine or have suffered from COVID in the six weeks before the IMG. We also evaluated the analytical characteristics of the outbreaks. Results: A total of 386 KB were studied. Of them, 86/218 (39.4%) were IMG performed pre- and 85/168 (50.6%) post-SV (029). The incidence of idiopathic nephrotic syndrome (INS), studied separately, was also significantly increased post-vaccination (n = 18 (10.7%)) compared to pre-vaccination (n = 11 (5%)) (p = 0.036). There were no differences in the incidence of vasculitis or IgA nephropathy. Up to 17 (20%) flares occurred 6 weeks before SARS-CoV-2 vaccination and only 2 (2.4%) within the first 6 weeks after SARS-CoV-2 infection. Within those 17 flares, the most common diagnosis was IgAN (n = 5 (29.4%)); a total of 14 (82.4%) received an mRNA vaccine and 9 (52.9%) took place after the 1st vaccine dose. There were 13 cases of minimal change disease (MCD) with debut/recurrence pre-SV and 20 MCD with debut/recurrence post-SV (p = 0.002). Conclusions: The incidence of IMG, INS and MCD flares in our center increased significantly after SARS-CoV-2 vaccination. Importantly, 20% of IMG flares took place within the first 6 weeks after receiving a vaccine dose, with the first dose being the riskiest one and IgAN the most frequent diagnosis., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, grant numbers PI17/00257, PI21/01292, RICORS RD21/0005/0016, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, and ERA-PerMed-JTC 2022 (ONAKI-ICI AC22/00029).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A predictive model of non-diabetic kidney disease in patients with diabetes mellitus and chronic kidney disease. A Spanish multi-center study, Modelo predictivo de enfermedad renal no diabética en los pacientes con diabetes mellitus y enfermedad renal crónica. Un estudio multicéntrico español

  • González Monte, Esther
  • López-Revuelta, Katia
  • Ibernon, Meritxell
  • López Espinosa, Diana
  • MARTIN-GÓMEZ, ADORACIÓN
  • Bermejo García, Sheila
  • Agraz Pamplona, Irene
  • Soler, María José
Kidney biopsy; Diabetes mellitus; Chronic kidney disease, Biopsia renal; Diabetes mellitus; Enfermedad renal crónica, Biòpsia renal; Diabetis mellitus; Malaltia renal crònica, Aims Kidney biopsy is increasing in patients with diabetes and around 50–60% of patients with diabetes have non-diabetic kidney disease (NDKD). Identifying NDKD is crucial since these patients have a better renal prognosis and survival compared to patients with diabetic nephropathy (DN). The objective of this study is to provide a clinical practice tool for through a predictive model of NDKD. Material and methods Observational and multicenter Spanish study of the pathological results of kidney biopsies in patients with diabetes from 2002 to 2014. A logistic regression analysis and the probability of presenting NDKD was calculated using a punctuation score. Results A total of 832 patients with diabetes and renal biopsy were analyzed. An accurate risk-predictive model for NDKD was developed with five top-ranked non-invasive clinical variables (age, serum creatinine, presence of diabetic retinopathy, microhematuria and peripheral vascular disease) obtaining a score for each one allowing for a proper prediction of NDKD. Conclusions In our study, we developed a risk-stratification score to calculate the probability of NDKD. This could be in a next future a useful tool for the clinical indication of renal biopsy in patients with diabetes and kidney disease., La realización de la biopsia renal está aumentando en los pacientes diabéticos, diagnosticándose entre el 50-60% de nefropatía no-diabética (NND). Este hecho es crucial dado que se ha demostrado una mejor supervivencia y pronóstico renal en la NND comparado con la nefropatía diabética (ND). El objetivo de este estudio es proporcionar una herramienta de práctica clínica a través de un modelo predictivo de NND. Material y métodos Estudio observacional multicéntrico español del resultado anatomo-patológico en los pacientes con diabetes y biopsia renal desde 2002 hasta el 2014. Un análisis de regresión logística y la probabilidad de presentar NND fue calculada mediante una puntuación obtenida. Resultados Un total de 832 pacientes fueron analizados. Se desarrolló un modelo predictivo de riesgo certero para la NND con 5 variables clínicas (edad, creatinina, presencia de retinopatía diabética, microhematuria y enfermedad vascular periférica) obteniendo una puntuación para cada una que permite una predicción adecuada de NND. Conclusiones En nuestro estudio, desarrollamos una puntuación de estratificación de riesgo para calcular la probabilidad de NND. Esto podría ser en un futuro próximo una herramienta útil para la indicación clínica de biopsia renal en los pacientes con diabetes y enfermedad renal., This work was supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, PI17/00257, PI21/01292, PI20/00744, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), EIN2020-1123381, BECA SENFRO 2021 and RD21/0005/0016 (RICORS 2040).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Paraneoplastic Syndrome After Kidney Transplantation: Frequency, Risk Factors, Differences to Paraneoplastic Occurrence of Glomerulonephritis in the Native Kidney, and Implications on Long-Term Kidney Graft Function

  • Zakrocka, Izabela
  • Nair, Gayatri
  • Jhaveri, Kenar D
  • Kronbichler, Andreas
  • Soler, María José
Glomerulonephritis; Paraneoplastic syndrome; Transplantation, Glomerulonefritis; Síndrome paraneoplàsica; Ttrasplantament, Glomerulonefritis; Síndrome paraneoplásico; Trasplante, Posttransplant malignancies are an important complication of solid organ transplantation. Kidney transplant recipients are at particularly high risk of cancer development. The most relevant risk factors of carcinogenesis are the use of immunosuppressive agents and oncogenic viral infections. Additionally, immune dysregulation caused by these factors may predispose to various types of organ damage. Paraneoplastic glomerular diseases are one of the most interesting and understudied cancer manifestations. The appropriate diagnosis of paraneoplastic glomerular damage can be challenging in kidney transplant recipients, due to factors inherent to concomitant medication and common comorbidities. Recent advances in the field of molecular and clinical nephrology led to a significant improvement in our understanding of glomerular diseases and their more targeted treatment. On the other hand, introduction of novel anticancer drugs tremendously increased patients’ survival, at the cost of kidney-related side effects. Our review aims to provide insights into diagnosis and treatment of paraneoplastic glomerular diseases, with a special attention to kidney transplant recipients., The authors declare that financial support was received for the research, authorship, and/or publication of this article. MS is supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, PI17/00257, PI20/00744, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), BECA SENFRO 2021, RD21/0005/0016 (RICORS 2040), and ERA-PerMed-JTC 2022 (ONAKI-ICI AC22/00029).
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Sodium-glucose cotransporter 2 inhibition, towards an indication to treat diabetic kidney disease

  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Navarro-González, Juan F.|||0000-0002-5015-7474
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Vergara, Ander|||0000-0003-1926-0147
  • Núñez, Julio|||0000-0003-1672-7119
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Martínez-Castelao, Alberto
  • Soler, María José|||0000-0003-3621-0766
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin-angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with overt DKD. However, the indication of this drug class is still blood glucose lowering in type 2 diabetic patients with estimated glomerular filtration rate >45 mL/min/1.73 m 2. Based on the new evidence, several scientific societies have emphasized the preferential prescription of SGLT2i for patients at risk of heart failure or kidney disease, but still within the limits set by health authorities. A rapid positioning of both the European Medicines Agency and the US Food and Drug Administration will allow patients with overt DKD to benefit from SGLT2i. Clinical experience suggests that SGLT2i safety management may in part mirror renin-angiotensin blockade safety management in patients with overt DKD. This review focuses on the rationale for an indication of SGTL2i in DKD. We further propose clinical steps for maximizing the safety of SGLT2i in DKD patients on other antidiabetic, BP or diuretic medication.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy

  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Soler, María José|||0000-0003-3621-0766
Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in native kidney biopsies from adults. In 2009, antibodies to the M-type receptor of phospholipase A2 (anti-PLA2R) were identified in idiopathic MN patients, both within the kidney and in the circulation. The clinical course of idiopathic MN is variable and ranges from spontaneous remission to end-stage renal disease. Clinical variables such as proteinuria levels, patient sex, age and renal function at diagnosis have been associated with renal MN progression. In this editorial, we update the importance of anti-PLA2R levels as a prognostic marker in idiopathic MN at the diagnosis of the disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Sodium-glucose cotransporter inhibitors, beyond glycaemic control

  • Vergara, Ander|||0000-0003-1926-0147
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Soler, María José|||0000-0003-3621-0766
Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium-glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated to reduce cardiovascular complications and slow diabetic kidney disease progression in patients with type 2 diabetes. The glycaemic control exerted by these drugs is not greater than the one achieved with other classical glucose-lowering medications such as sulphonylureas. For that reason, plausible renoprotective mechanisms independent from glycaemic control have been proposed such as blood pressure control, body weight loss, intraglomerular pressure reduction and a decrease in urinary proximal tubular injury biomarkers. Interestingly, the hypothesis that SGLT2 inhibitors have a direct renoprotective effect has been addressed in diabetic and non-diabetic models. In this editorial, we update the different postulated mechanisms involved in the cardiorenal protection afforded by SGLT2 inhibition in chronic kidney disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Challenges in primary focal segmental glomerulosclerosis diagnosis, from the diagnostic algorithm to novel biomarkers

  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Vergara, Ander|||0000-0003-1926-0147
  • García-Carro, Clara|||0000-0002-5130-603X
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Moreso, Francesc|||0000-0002-7267-3963
  • Seron, Daniel|||0000-0003-2054-653X
  • López-Hellín, Joan|||0000-0001-7286-3882
  • Soler, María José|||0000-0003-3621-0766
Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30-50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

SGLT2 inhibitors for non-diabetic kidney disease, drugs to treat CKD that also improve glycaemia

  • Fernández-Fernández, Beatriz
  • Sarafidis, Pantelis|||0000-0002-9174-4018
  • Kanbay, Mehmet|||0000-0002-1297-0675
  • Navarro-González, Juan F.|||0000-0002-5015-7474
  • Soler, María José|||0000-0003-3621-0766
  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Ortiz, Alberto|||0000-0002-9805-9523
Sodium-glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluationtrial. More recently, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial showed that dapagliflozin improved CV outcomes in patients with HF with or without diabetes. Protection from HF in non-diabetics was confirmed for empagliflozin in the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) trial. A meta-analysis of DAPA-HF and EMPEROR-Reduced confirmed reductions in all-cause and CV death and the combined risk of CV death or worsening HF, as well as in the composite renal endpoint {hazard ratio [HR] 0.62 [95% confidence interval (CI) 0.43-0.90]} without differences based on the presence of diabetes or baseline estimated glomerular filtration rate (eGFR). Moreover, the Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (DAPA-CKD) showed that dapagliflozin as an add-on over renin-angiotensin system blockade in patients with chronic kidney disease (CKD; with or without T2DM) reduced the HR for the primary endpoint (time to the first occurrence of ≥50% eGFR decline, end-stage kidney disease or renal or CV death) to 0.61 (95% CI 0.51-0.72) and for the secondary endpoints of worsening renal function or death from kidney failure [HR 0.56 (95% CI 0.45-0.68)], hospitalization for HF or CV death [HR 0.71 (95% CI 0.55-0.92)] and all-cause mortality [HR 0.69 (95% CI 0.53-0.88)]. These beneficial effects were consistent in patients with and without T2DM. In conclusion, SGLT2 inhibitors offer CV and kidney protection in both diabetic and non-diabetic CKD and, additionally, improve glycaemic control in T2DM, making them first-line therapy for CKD independent from diabetic status.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impacto de la pandemia COVID-19 en los servicios de Nefrología españoles

  • Soler, María José|||0000-0003-3621-0766
  • Macia Heras, Manuel
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Del Pino Y Pino, Mª Dolores
  • Salgueira Lazo, Mercedes
La pandemia de la infección por el coronavirus tipo 2 del síndrome respiratorio agudo grave o SARS-CoV-2, causante de la enfermedad por coronavirus de 2019 (COVID-19), ha precisado una transformación drástica de los hospitales y, por consiguiente, de los servicios de Nefrología de España. Desde la Sociedad Española de Nefrología se ha realizado una encuesta a los jefes de servicios de Nefrología de España abordando la reorganización de los servicios de Nefrología y la actividad en la época de mayor afectación por COVID-19. Hemos preguntado por la integración de los nefrólogos en equipos COVID-19, la actividad asistencial de hospitalización de Nefrología (ingresos programados, biopsias renales), la realización de cirugías programadas como los accesos vasculares o la implantación de catéteres peritoneales, la suspensión o no del programa de trasplante renal y la transformación de las consultas externas de Nefrología. En el trabajo actual se detallan la adaptación y la transformación de los servicios de Nefrología en la pandemia COVID-19 en España. Durante dicho periodo se han suspendido los ingresos programados en los servicios de Nefrología, la realización de cirugías/biopsias programadas y ha disminuido en más de un 75% el programa de trasplante renal. Es de interés mencionar que las consultas externas de Nefrología se han realizado mayoritariamente telefónicamente. En conclusión, la pandemia ha impactado claramente en la actividad clínica en los servicios de Nefrología españoles disminuyendo la actividad programada y los trasplantes renales y modificando la actividad en consultas externas. Un plan de transformación asistencial e implementación de telemedicina en Nefrología parece necesario y de gran utilidad en un futuro próximo.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Endothelial ADAM17 Expression in the Progression of Kidney Injury in an Obese Mouse Model of Pre-Diabetes

  • Palau, Vanesa|||0000-0002-3210-7924
  • Jarrín, Josué|||0000-0001-9172-3383
  • Villanueva, Sofia
  • Benito, David|||0000-0001-5413-5005
  • Márquez, Eva
  • Rodríguez García, Eva
  • Soler, María José|||0000-0003-3621-0766
  • Oliveras i Serrano, Anna|||0000-0002-5503-545X
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Sans, Laia|||0000-0002-3628-9489
  • Crespo, Marta|||0000-0001-6992-6379
  • Pascual, Julio|||0000-0002-4735-7838
  • Barrios, Clara|||0000-0003-0492-4107
  • Riera Oliva, Marta|||0000-0003-4362-7965
Disintegrin and metalloproteinase domain 17 (ADAM17) activates inflammatory and fibrotic processes through the shedding of various molecules such as Tumor Necrosis Factor-α (TNF-α) or Transforming Growht Factor-α (TGF-α). There is a well-recognised link between TNF-α, obesity, inflammation, and diabetes. In physiological situations, ADAM17 is expressed mainly in the distal tubular cell while, in renal damage, its expression increases throughout the kidney including the endothelium. The aim of this study was to characterize, for the first time, an experimental mouse model fed a high-fat diet (HFD) with a specific deletion of Adam17 in endothelial cells and to analyse the effects on different renal structures. Endothelial Adam17 knockout male mice and their controls were fed a high-fat diet, to induce obesity, or standard rodent chow, for 22 weeks. Glucose tolerance, urinary albumin-to-creatinine ratio, renal histology, macrophage infiltration, and galectin-3 levels were evaluated. Results showed that obese mice presented higher blood glucose levels, dysregulated glucose homeostasis, and higher body weight compared to control mice. In addition, obese wild-type mice presented an increased albumin-to-creatinine ratio; greater glomerular size and mesangial matrix expansion; and tubular fibrosis with increased galectin-3 expression. Adam17 deletion decreased the albumin-to-creatinine ratio, glomerular mesangial index, and tubular galectin-3 expression. Moreover, macrophage infiltration in the glomeruli of obese Adam17 knockout mice was reduced as compared to obese wild-type mice. In conclusion, the expression of ADAM17 in endothelial cells impacted renal inflammation, modulating the renal function and histology in an obese pre-diabetic mouse model.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Transcriptome Analysis in Renal Transplant Biopsies Not Fulfilling Rejection Criteria

  • Moreso, Francesc|||0000-0002-7267-3963
  • Sellarès, Joana
  • Soler, María José|||0000-0003-3621-0766
  • Seron, Daniel|||0000-0003-2054-653X
The clinical significance of renal transplant biopsies displaying borderline changes suspicious for T-cell mediated rejection (TCMR) or interstitial fibrosis and tubular atrophy (IFTA) with interstitial inflammation has not been well defined. Molecular profiling to evaluate renal transplant biopsies using microarrays has been shown to be an objective measurement that adds precision to conventional histology. We review the contribution of transcriptomic analysis in surveillance and indication biopsies with borderline changes and IFTA associated with variable degrees of inflammation. Transcriptome analysis applied to biopsies with borderline changes allows to distinguish patients with rejection from those in whom mild inflammation mainly represents a response to injury. Biopsies with IFTA and inflammation occurring in unscarred tissue display a molecular pattern similar to TCMR while biopsies with IFTA and inflammation in scarred tissue, apart from T-cell activation, also express B cell, immunoglobulin and mast cell-related genes. Additionally, patients at risk for IFTA progression can be identified by genes mainly reflecting fibroblast dysregulation and immune activation. At present, it is not well established whether the expression of rejection gene transcripts in patients with fibrosis and inflammation is the consequence of an alloimmune response, tissue damage or a combination of both.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19

  • Fernández-Fernández, Beatriz
  • D'Marco, Luis|||0000-0003-0148-891X
  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Kanbay, Mehmet|||0000-0002-1297-0675
  • Luis-Lima, Sergio|||0000-0003-3540-8252
  • Porrini, Esteban
  • Sarafidis, Pantelis|||0000-0002-9174-4018
  • Soler, María José|||0000-0003-3621-0766
  • Ortiz, Alberto|||0000-0002-9805-9523
Hospital admissions and mortality from the Coronavirus disease 2019 (COVID-19) pandemic are spreading throughout the world, and second and third waves are thought to be likely. Risk factors for severe COVID-19 include diabetes, chronic kidney disease and cardiovascular disease. Currently, there is no vaccine and no approved therapy. Therapeutic approaches are aimed at preventing viral replication and spread, limiting the impact of the inflammatory overdrive (cytokine storm), preventing thromboembolic complications and replacing or supporting organ function. However, despite organ support, mortality is currently 65% for those receiving advanced respiratory support and 78% for those requiring renal replacement therapies. Thus, efforts should be made to provide adjuvant organ protection therapy. This may imply novel therapies in clinical development (e.g., the Fas ligand trap asunercept), but uptake of repurposed drugs already in clinical use may be faster. In this regard, sodium glucose co-transporter-2 (SGLT2) inhibitors were recently shown to protect the heart and kidney both within and outside of a diabetic milieu context. Further, preclinical data support a beneficial effect for the lung. We now discuss the potential benefits and risks of SGLT2 inhibitors in COVID-19 and an ongoing clinical trial testing the impact of dapagliflozin on outcomes in COVID-19 patients with respiratory failure
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes

  • García-Carro, Clara|||0000-0002-5130-603X
  • Vergara, Ander|||0000-0003-1926-0147
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Espinel Garuz, Eugenia
  • Seron, Daniel|||0000-0003-2054-653X
  • Soler, María José|||0000-0003-3621-0766
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the developed world. Until 2016, the only treatment that was clearly demonstrated to delay the DKD was the renin-angiotensin system blockade, either by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. However, this strategy only partially covered the DKD progression. Thus, new strategies for reno-cardiovascular protection in type 2 diabetic patients are urgently needed. In the last few years, hypoglycaemic drugs, such as sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, demonstrated a cardioprotective effect, mainly in terms of decreasing hospitalization for heart failure and cardiovascular death in type 2 diabetic patients. In addition, these drugs also demonstrated a clear renoprotective effect by delaying DKD progression and decreasing albuminuria. Another hypoglycaemic drug class, dipeptidyl peptidase 4 inhibitors, has been approved for its use in patients with advanced chronic kidney disease, avoiding, in part, the need for insulinization in this group of DKD patients. Studies in diabetic and non-diabetic experimental models suggest that these drugs may exert their reno-cardiovascular protective effect by glucose and non-glucose dependent mechanisms. This review focuses on newly demonstrated strategies that have shown reno-cardiovascular benefits in type 2 diabetes and that may change diabetes management algorithms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation

  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Puig-Gay, Natalia|||0000-0002-4703-0165
  • Vergara, Ander|||0000-0003-1926-0147
  • Gabaldon, Maria-Alejandra
  • Sellarés, Joana
  • Villena-Ortiz, Yolanda|||0000-0003-0925-0498
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Moreso, Francesc|||0000-0002-7267-3963
  • Soler, María José|||0000-0003-3621-0766
  • Seron, Daniel|||0000-0003-2054-653X
  • López-Hellín, Joan|||0000-0001-7286-3882
A major complication of primary focal segmental glomerulosclerosis (FSGS) is its recurrence after kidney transplantation that happens in 30 to 40% of the patients. The diagnosis of these relapses is not always easy as the histological lesions are not highly specific and appear after the proteinuria increase. Currently, there are no accurate biomarkers to detect FSGS recurrence. Our group identified a modified form of Apolipoprotein A-I (ApoA-I), named ApoA-Ib, specifically present in the urine of recurrent FSGS patients after kidney transplantation. Aberrant forms of ApoA-I have also been described in the urine of native primary FSGS patients; this feature has been associated with prominent staining of ApoA-I at the apical membrane of the tubular cells. In this study, we aim to analyze the ApoA-I distribution in kidney allograft biopsies of recurrent FSGS patients. We detected ApoA-I by immunohistochemistry in kidney allograft biopsies of patients with FSGS relapse after kidney transplantation and in kidney allograft biopsies of patients with a disease different from FSGS in the native kidney (non-FSGS). In recurrent FSGS patients, ApoA-I was prominently localized at the brush border of the tubular cells, while in the non-FSGS patients, ApoA-I was found along the cytoplasm of the tubular cells. The localization of ApoA-I at the brush border of the tubular cells is a specific feature of primary FSGS in relapse. This suggests that ApoA-I staining in kidney biopsies, coupled with ApoA-Ib measurement in urine, could be used as a diagnostic tool of primary FSGS relapse after kidney transplantation due to its highly specific tubular distribution.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice

  • Vergara, Ander|||0000-0003-1926-0147
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Llorens-Cebria, Carmen|||0000-0002-3611-1816
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Martinez-Diaz, Irene|||0000-0001-5849-7900
  • Martos, Nerea
  • Dominguez-Báez, Pamela
  • Molina Van den Bosch, Mireia
  • Bermejo García, Sheila|||0000-0002-3611-4830
  • Pieper, Michael Paul
  • Benito Villabriga, Begoña|||0000-0002-8668-1251
  • Soler, María José|||0000-0003-3621-0766
Treatments with sodium-glucose 2 cotransporter inhibitors (SGLT2i) or endothelin receptor antagonists (ERA) have shown cardiorenal protective effects. The present study aimed to evaluate the cardiorenal beneficial effects of the combination of SGLT2i and ERA on top of renin-angiotensin system (RAS) blockade. Type 2 diabetic mice (db/db) were treated with different combinations of an SGLT2i (empagliflozin), an ERA (atrasentan), and an angiotensin-converting enzyme inhibitor (ramipril) for 8 weeks. Vehicle-treated diabetic mice and non-diabetic mice were included as controls. Weight, blood glucose, blood pressure, and kidney and heart function were monitored during the study. Kidneys and heart were collected for histological examination and to study the intrarenal RAS. Treatment with empagliflozin alone or combined significantly decreased blood glucose compared to vehicle-treated db/db. The dual and triple therapies achieved significantly greater reductions in diastolic blood pressure than ramipril alone. Compared to vehicle-treated db/db, empagliflozin combined with ramipril or in triple therapy significantly prevented GFR increase, but only the triple combination exerted greater protection against podocyte loss. In the heart, empagliflozin alone or combined reduced cardiac isovolumetric relaxation time (IVRT) and left atrium (LA) diameter as compared to vehicle-treated db/db. However, only the triple therapy was able to reduce cardiomyocyte area. Importantly, the add-on triple therapy further enhanced the intrarenal ACE2/Ang(1-7)/Mas protective arm of the RAS. These data suggest that triple therapy with empagliflozin, atrasentan and ramipril show synergistic cardiorenal protective effects in a type 2 diabetic mouse model.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Expert Clinical Management of Severe Immune-Related Adverse Events, Results from a Multicenter Survey on Hot Topics for Management

  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Soler, María José|||0000-0003-3621-0766
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Bermejo García, Sheila|||0000-0002-3611-4830
  • Bruera, Sebastian
  • Suarez-Almazor, Maria E.
There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area. Fifty-six surveys were completed (17 IIH, 20 renal irAEs, and 19 myositis). All experts agreed on performing imaging in every suspected case of severe IIH. Sixty-five percent agreed on performing a liver biopsy in patients not responding to corticosteroids. The most common indication for corticosteroid use (59%) was for severe IIH not improving after discontinuation of ICIs. Additionally, 60% of the experts agreed on performing a biopsy for stage 2/3 acute kidney injury (AKI), and 70% recommended imaging for any stage of AKI. Thirty-five percent favored corticosteroids in AKI patients with creatinine levels 2-3-fold above baseline. For myositis, 58% would recommend a muscle biopsy in a patient with weakness and creatine kinase levels of 5000 U/L; 47% would also opt for an endomyocardial biopsy when the troponin levels are increased. Fifty-eight percent recommended oral corticosteroids for myositis, and 37% recommended additional therapy, mainly immunoglobulins. These results show substantial differences in expert practice patterns for the management of severe liver, kidney, and muscular irAEs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Redefining the Role of ADAM17 in Renal Proximal Tubular Cells and Its Implications in an Obese Mouse Model of Pre-Diabetes

  • Palau, Vanesa|||0000-0002-3210-7924
  • Villanueva, Sofia
  • Jarrín, Josué|||0000-0001-9172-3383
  • Benito, David|||0000-0001-5413-5005
  • Márquez, Eva
  • Rodríguez García, Eva
  • Soler, María José|||0000-0003-3621-0766
  • Oliveras i Serrano, Anna|||0000-0002-5503-545X
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Sans, Laia|||0000-0002-3628-9489
  • Soler, María José|||0000-0003-3621-0766
  • Pascual, Julio|||0000-0002-4735-7838
  • Barrios, Clara|||0000-0003-0492-4107
  • Riera Oliva, Marta|||0000-0003-4362-7965
Acute and chronic kidney lesions induce an increase in A Disintegrin And Metalloproteinase domain 17 (ADAM17) that cleaves several transmembrane proteins related to inflammatory and fibrotic pathways. Our group has demonstrated that renal ADAM17 is upregulated in diabetic mice and its inhibition decreases renal inflammation and fibrosis. The purpose of the present study was to analyze how Adam17 deletion in proximal tubules affects different renal structures in an obese mice model. Tubular Adam17 knockout male mice and their controls were fed a high-fat diet (HFD) for 22 weeks. Glucose tolerance, urinary albumin-to-creatinine ratio, renal histology, and pro-inflammatory and pro-fibrotic markers were evaluated. Results showed that wild-type mice fed an HFD became obese with glucose intolerance and renal histological alterations mimicking a pre-diabetic condition; consequently, greater glomerular size and mesangial expansion were observed. Adam17 tubular deletion improved glucose tolerance and protected animals against glomerular injury and prevented podocyte loss in HFD mice. In addition, HFD mice showed more glomerular macrophages and collagen accumulation, which was prevented by Adam17 deletion. Galectin-3 expression increased in the proximal tubules and glomeruli of HFD mice and ameliorated with Adam17 deletion. In conclusion, Adam17 in proximal tubules influences glucose tolerance and participates in the kidney injury in an obese pre-diabetic murine model. The role of ADAM17 in the tubule impacts on glomerular inflammation and fibrosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunotherapy and the Spectrum of Kidney Disease, Should We Individualize the Treatment?

  • Bermejo García, Sheila|||0000-0002-3611-4830
  • Bolufer, Mónica|||0000-0002-3379-7031
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Soler, María José|||0000-0003-3621-0766
The new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The coexistence of diabetic retinopathy and diabetic nephropathy is associated with worse kidney outcomes

  • Bermejo García, Sheila|||0000-0002-3611-4830
  • González, Ester
  • López-Revuelta, Katia
  • Ibernon, Meritxell
  • López, Diana
  • Martín-Gómez, Adoración
  • Garcia-Osuna, Rosa
  • Linares, Tania
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Martín, Nàdia
  • Barros, Xoana|||0000-0001-9690-9769
  • Marco Rusiñol, Helena|||0000-0002-7229-8729
  • Navarro Diaz, Maruja Isabel|||0000-0003-3001-0595
  • Esparza, Noemí
  • Elias, Sandra
  • Coloma, Ana|||0000-0002-1773-9560
  • Robles, Nicolás Roberto|||0000-0003-4984-6691
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Poch, Esteban|||0000-0002-6492-024X
  • Rodas, Lidia
  • Lozano, Víctor
  • Fernández-Fernández, Beatriz
  • Hernández, Eduardo
  • Martínez, Maria Isabel
  • Stanescu, Ramona Ionela
  • Moirón, José Pelayo
  • García Fernández, Nuria|||0000-0003-1082-0806
  • Goicoechea, Marian|||0000-0002-7614-0830
  • Calero, Francesca|||0000-0002-5758-0769
  • Bonet Sol, Josep
  • Liaño, Fernando
  • Pascual, Julio|||0000-0002-4735-7838
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
  • Praga, Manuel|||0000-0001-9270-1071
  • Fulladosa, Xavier|||0000-0003-1974-9874
  • Soler, María José|||0000-0003-3621-0766
Up to 50-60% of patients with diabetes have non-diabetic kidney disease (NDKD) on kidney biopsy. Diabetic retinopathy (DR) is a microvascular complication of diabetes frequently associated with diabetic nephropathy (DN). The objective of the current study was to investigate the kidney outcomes and survival in patients with biopsy diagnoses of DN and NDKD according to the presence of DR. We conducted an observational, multicentre and retrospective study of the pathological findings of renal biopsies from 832 consecutive patients with diabetes from 2002 to 2014 from 18 nephrology departments. The association of DR with kidney replacement therapy (KRT) or survival was assessed by Kaplan-Meier and Cox regression analyses. Of 832 patients with diabetes and renal biopsy, 768 had a retinal examination and 221/768 (22.6%) had DR. During a follow-up of 10 years, 288/760 (37.9%) patients with follow-up data needed KRT and 157/760 (20.7%) died. The incidence of KRT was higher among patients with DN (alone or with NDKD) and DR [103/175 (58.9%)] than among patients without DR [88/216 (40.7%), P <.0001]. The incidence of KRT was also higher among patients with only NDKD and DR than among those without DR [18/46 (39.1%) versus 79/331 (23.9%), P <.0001]. In multivariate analysis, DR or DN were independent risk factors for KRT {hazard ratio [HR] 2.48 [confidence interval (CI) 1.85-3.31], P <.001}. DN (with or without DR) was also identified as an independent risk factor for mortality [HR 1.81 (CI 1.26-2.62), P =.001]. DR is associated with a higher risk of progression to kidney failure in patients with histological DN and in patients with NDKD.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

A predictive model of non-diabetic kidney disease in patients with diabetes mellitus and chronic kidney disease. A Spanish multi-center study, Modelo predictivo de enfermedad renal no diabética en los pacientes con diabetes mellitus y enfermedad renal crónica. Un estudio multicéntrico español

  • González Monte, Esther
  • López-Revuelta, Katia
  • Ibernon, Meritxell
  • López Espinosa, Diana
  • MARTIN-GÓMEZ, ADORACIÓN
  • Bermejo García, Sheila
  • Agraz Pamplona, Irene
  • Soler, María José
Kidney biopsy; Diabetes mellitus; Chronic kidney disease, Biopsia renal; Diabetes mellitus; Enfermedad renal crónica, Biòpsia renal; Diabetis mellitus; Malaltia renal crònica, Aims Kidney biopsy is increasing in patients with diabetes and around 50–60% of patients with diabetes have non-diabetic kidney disease (NDKD). Identifying NDKD is crucial since these patients have a better renal prognosis and survival compared to patients with diabetic nephropathy (DN). The objective of this study is to provide a clinical practice tool for through a predictive model of NDKD. Material and methods Observational and multicenter Spanish study of the pathological results of kidney biopsies in patients with diabetes from 2002 to 2014. A logistic regression analysis and the probability of presenting NDKD was calculated using a punctuation score. Results A total of 832 patients with diabetes and renal biopsy were analyzed. An accurate risk-predictive model for NDKD was developed with five top-ranked non-invasive clinical variables (age, serum creatinine, presence of diabetic retinopathy, microhematuria and peripheral vascular disease) obtaining a score for each one allowing for a proper prediction of NDKD. Conclusions In our study, we developed a risk-stratification score to calculate the probability of NDKD. This could be in a next future a useful tool for the clinical indication of renal biopsy in patients with diabetes and kidney disease., La realización de la biopsia renal está aumentando en los pacientes diabéticos, diagnosticándose entre el 50-60% de nefropatía no-diabética (NND). Este hecho es crucial dado que se ha demostrado una mejor supervivencia y pronóstico renal en la NND comparado con la nefropatía diabética (ND). El objetivo de este estudio es proporcionar una herramienta de práctica clínica a través de un modelo predictivo de NND. Material y métodos Estudio observacional multicéntrico español del resultado anatomo-patológico en los pacientes con diabetes y biopsia renal desde 2002 hasta el 2014. Un análisis de regresión logística y la probabilidad de presentar NND fue calculada mediante una puntuación obtenida. Resultados Un total de 832 pacientes fueron analizados. Se desarrolló un modelo predictivo de riesgo certero para la NND con 5 variables clínicas (edad, creatinina, presencia de retinopatía diabética, microhematuria y enfermedad vascular periférica) obteniendo una puntuación para cada una que permite una predicción adecuada de NND. Conclusiones En nuestro estudio, desarrollamos una puntuación de estratificación de riesgo para calcular la probabilidad de NND. Esto podría ser en un futuro próximo una herramienta útil para la indicación clínica de biopsia renal en los pacientes con diabetes y enfermedad renal., This work was supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, PI17/00257, PI21/01292, PI20/00744, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), EIN2020-1123381, BECA SENFRO 2021 and RD21/0005/0016 (RICORS 2040).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Epidemiology of Immune-Mediated Glomerulopathies before and after SARS-CoV-2 Vaccination: A Tertiary Referral Hospital Experience

  • Zamora Carrillo, Jorge Iván
  • Lopez Martinez, Marina
  • Patricio Liebana, Marc
  • León Román, Juan
  • Bermejo Garcia, Sheila
  • Vergara Arana, Ander
  • Agraz Pamplona, Irene
  • Azancot Rivero, M Antonieta
  • Toapanta Gaibor, Nestor Gabriel
  • Gabaldon Dominguez, Alejandra
  • Soler Romeo, Maria Jose
  • Ramos Terrades, Natalia
SARS-CoV-2; Immune-mediated glomerulopathy; Vaccine, SARS-CoV-2; Glomerulopatía inmunomediada; Vacuna, SARS-CoV-2; Glomerulopatia immunomediada; Vacuna, Background: Vaccination is a known trigger for the appearance of immune-mediated glomerulopathies (IMG). The appearance of IMG after SARS-CoV-2 vaccination with suspected causality has been described. Our aim is to analyze the incidence of IMG flares before and after SARS-CoV-2 vaccination in our center. Methods: All persons with native kidney biopsy (KB) from January 2019 to March 2022 in our center were included in the study. We compared the incidence of IMG before and after the start of vaccination. We also collected information about whether the patients had received a SARS-CoV-2 vaccine or have suffered from COVID in the six weeks before the IMG. We also evaluated the analytical characteristics of the outbreaks. Results: A total of 386 KB were studied. Of them, 86/218 (39.4%) were IMG performed pre- and 85/168 (50.6%) post-SV (029). The incidence of idiopathic nephrotic syndrome (INS), studied separately, was also significantly increased post-vaccination (n = 18 (10.7%)) compared to pre-vaccination (n = 11 (5%)) (p = 0.036). There were no differences in the incidence of vasculitis or IgA nephropathy. Up to 17 (20%) flares occurred 6 weeks before SARS-CoV-2 vaccination and only 2 (2.4%) within the first 6 weeks after SARS-CoV-2 infection. Within those 17 flares, the most common diagnosis was IgAN (n = 5 (29.4%)); a total of 14 (82.4%) received an mRNA vaccine and 9 (52.9%) took place after the 1st vaccine dose. There were 13 cases of minimal change disease (MCD) with debut/recurrence pre-SV and 20 MCD with debut/recurrence post-SV (p = 0.002). Conclusions: The incidence of IMG, INS and MCD flares in our center increased significantly after SARS-CoV-2 vaccination. Importantly, 20% of IMG flares took place within the first 6 weeks after receiving a vaccine dose, with the first dose being the riskiest one and IgAN the most frequent diagnosis., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, grant numbers PI17/00257, PI21/01292, RICORS RD21/0005/0016, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, and ERA-PerMed-JTC 2022 (ONAKI-ICI AC22/00029).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Paraneoplastic Syndrome After Kidney Transplantation: Frequency, Risk Factors, Differences to Paraneoplastic Occurrence of Glomerulonephritis in the Native Kidney, and Implications on Long-Term Kidney Graft Function

  • Zakrocka, Izabela
  • Nair, Gayatri
  • Jhaveri, Kenar D
  • Kronbichler, Andreas
  • Soler, María José
Glomerulonephritis; Paraneoplastic syndrome; Transplantation, Glomerulonefritis; Síndrome paraneoplàsica; Ttrasplantament, Glomerulonefritis; Síndrome paraneoplásico; Trasplante, Posttransplant malignancies are an important complication of solid organ transplantation. Kidney transplant recipients are at particularly high risk of cancer development. The most relevant risk factors of carcinogenesis are the use of immunosuppressive agents and oncogenic viral infections. Additionally, immune dysregulation caused by these factors may predispose to various types of organ damage. Paraneoplastic glomerular diseases are one of the most interesting and understudied cancer manifestations. The appropriate diagnosis of paraneoplastic glomerular damage can be challenging in kidney transplant recipients, due to factors inherent to concomitant medication and common comorbidities. Recent advances in the field of molecular and clinical nephrology led to a significant improvement in our understanding of glomerular diseases and their more targeted treatment. On the other hand, introduction of novel anticancer drugs tremendously increased patients’ survival, at the cost of kidney-related side effects. Our review aims to provide insights into diagnosis and treatment of paraneoplastic glomerular diseases, with a special attention to kidney transplant recipients., The authors declare that financial support was received for the research, authorship, and/or publication of this article. MS is supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, PI17/00257, PI20/00744, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), BECA SENFRO 2021, RD21/0005/0016 (RICORS 2040), and ERA-PerMed-JTC 2022 (ONAKI-ICI AC22/00029).